Skip to main content

Advertisement

Table 3 Multivariate analysis of prognostic factors for OS and PFS of patients with DLBCL

From: Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study

Variate OS PFS
HR 95% CI P HR 95% CI P
Age 1.38 1.69–9.40 < 0.01 0.39 0.87–2.51 0.15
Clinical stage − 0.39 0.22–2.06 0.57 0.69 1.23–3.23 0.01
B symptoms − 0.93 0.12–1.35 0.63 0.45 0.97–2.56 0.07
Spleen involvement − 0.05 0.24–3.87 0.95 0.34 0.74–2.67 0.30
IPI 1.01 0.59–12.70 0.20 0.02 0.51–2.04 0.96
LDH 0.29 0.49–3.67 0.57 0.24 0.76–2.15 0.35
β2-MG 0.02 0.33–3.18 0.98   
Rituximab − 0.13 0.34–2.26 0.80   
CR after first-line chemotherapy − 1.54 0.09–0.49 < 0.01 − 0.24 0.48–1.27 0.33
PD-L1 expression in tumor cells 1.40 1.61–10.23 < 0.01 0.46 1.00–2.51 0.05
  1. IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death ligand 1, not included